Attention Deficit Hyperactivity Disorder
Conditions
Interventions
Heathy Control:NO
ADHD:after baseline assessment, each ADHD patient starts taking methylphenidate
ADHD-Placebo:during baseline assessment, single dose of placebo before methylphenidate
ADHD-MPH:during baseline assessment, single dose of methylphenidate before palcebo
Sponsors
Shenzhen Children's Hospital
Eligibility
Sex/Gender
All
Age
6 Years to 15 Years
Inclusion criteria
Inclusion criteria: The diagnosis of ADHD was first made by child psychiatrists through clinical interviews. In addition, all participants and their parents were interviewed by a clinician using a semi-structured tool, the Schedule for Affective Disorders and Schizophrenia for school-Age Children-Present and Lifetime version (K-SADS-PL) (Kaufman et al., 1997), to confirm or rule out any psychiatric diagnosis. The parent who knew the child best was regarded as the primary informant. other inclusion criteria include: 1) aged 6-15 years, right hand dominant; 2) no prior history of head injury with loss of consciousness; 3) no signs of neurological abnormalities or other physical diseases; 4)a full-scale IQ above 80; 5) no visual problem; 6) no MRI contraindications; 7) no visible abnormalities (examined by an experienced radiologist, e.g., cyst) on the MRI images.
Exclusion criteria
Exclusion criteria: exclusion criteria for the ADHD group: 1) obvious anxiety or agitation; 2) allergies to methyphenidate; 3) glaucoma; 4) family history or present diagnosis of Tourrete Symdrome; 5) history of taking MAOI in the past 14 days; 6) history of epilepsy or abnormality in EEG; 7) any sign of stricture of digestive tract (either physical or phathological), or diffuculty in swallowing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADHD symptoms;resting state brain function;brain white matter microstructure; | — |
Secondary
| Measure | Time frame |
|---|---|
| cognitive function; | — |
Countries
China
Contacts
Public ContactZhaomin Wu
Outcome results
None listed